HomeInsightsStock Comparison

Alembic Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Alembic Pharmaceuticals Ltd vs Syncom Formulations India Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 1015 as of 22 Jul 15:30.
  • The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 28 on March 2022 to 31.3 on March 2025 . This represents a CAGR of 1.87% over 6 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 14572 crore on March 2022 to ₹ 18265 crore on March 2025 . This represents a CAGR of 3.84% over 6 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 1783 crore as compare to the Dec '24 revenue of ₹ 1702 crore. This represent the growth of 4.77% The revenue of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 155.83 crore as compare to the Dec '24 revenue of ₹ 131.57 crore. This represent the growth of 18.44%.
  • The ebitda of Alembic Pharmaceuticals Ltd for the Mar '25 is ₹ 285.46 crore as compare to the Dec '24 ebitda of ₹ 270.08 crore. This represent the growth of 5.69% The ebitda of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 24.7 crore as compare to the Dec '24 ebitda of ₹ 18.77 crore. This represent the growth of 31.59%.
  • The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 120.6 crore to ₹ 156.63 crore over 8 quarters. This represents a CAGR of 13.96% The net profit of Syncom Formulations (India) Ltd changed from ₹ 4.4 crore to ₹ 17.69 crore over 8 quarters. This represents a CAGR of 100.51% .
  • The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 19.45 % on March 2020 to 42.97 % on March 2025 . This represents a CAGR of 14.12% over 6 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alembic Pharmaceuticals Ltd

  • Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
  • The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
  • The company is engaged in pharmaceuticals business.
  • As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Syncom Formulations (India) Ltd

  • Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
  • The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
  • Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
  • Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

Alembic Pharmaceuticals Ltd News Hub

News

Alembic Pharmaceuticals to convene board meeting

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 5 ...

Read more

21 Jul 2025 17:03

News

Alembic Pharmaceuticals appoints Sr. Vice President - SCM & Operations

Alembic Pharmaceuticals has appointed Dr. Sachin Ghosalkar is appointed as Sr. Vice Presid...

Read more

21 Jul 2025 14:08

News

Alembic Pharma appoints G. Krishnan as new CFO

Krishnan is a seasoned finance professional with over 22 years of experience across the ph...

Read more

07 Jul 2025 14:58

News

Alembic Pharmaceuticals announces acquisition of Utility Therapeutics

Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acqui...

Read more

03 Jul 2025 09:15

News

Alembic Pharma inks deal to acquire Utility Therapeutics for $12 million

Utility Therapeutics is involved in the development and approval of two brand pharmaceutic...

Read more

03 Jul 2025 10:40

News

Alembic Pharma jumps after receiving USFDA nod for Doxorubicin Hydrochloride Injection

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD)...

Read more

30 Jun 2025 10:12

Syncom Formulations (India) Ltd News Hub

News

Syncom Formulations (India) schedules board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

14 May 2025 14:06

News

Syncom Formulations (India) to convene board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

05 Nov 2024 14:12

News

Syncom Formulations (India) schedules AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 17:48

News

Syncom Formulations (India) to hold AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 10:30

News

Syncom Formulations gains after Q1 PAT rises over 73% YoY

Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total e...

Read more

13 Aug 2024 13:37

News

Syncom Formulations (India) announces board meeting date

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

06 Aug 2024 11:37

SWOT Analysis Of Alembic Pharmaceuticals Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Syncom Formulations (India) Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Alembic Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Syncom Formulations (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Syncom Formulations (India) Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 19,963 Cr while Market cap of Syncom Formulations (India) Ltd is 1,713 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd?

As of July 22, 2025, the Alembic Pharmaceuticals Ltd stock price is INR ₹1015.65. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹18.23.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions